In 1–5% of glioblastomas, the 1p36 locus was reported to be homozygously deleted which frequently includes ENO1. As a consequence, patients with such tumours should be more responsive to glycolysis inhibition despite the fact that ENO2 compensates for ENO1 deficiency to some extent. This evidence concerns the gene ENO2 and glioblastoma.